Key result
Late relapse (>2 years) and strictly localized relapse of Ewing sarcoma were associated with better 5-year overall survival (29% vs 7% for late vs early relapse; 24% for local relapse, P<0.001).
Population
714 patients with first recurrence of Ewing sarcoma treated within the Cooperative Ewing Sarcoma Studies 81…
Design
Cohort
Follow-up
Median 2.2 years from diagnosis of primary disease
Authors
Loading...
Poor survival after Ewing sarcoma relapse warrants novel therapies; leaves open validation of late/local prognostic factors in trials.
Cohort (n=714)
Yes
p-value: p=< 0.001
In patients with relapsed Ewing sarcoma, overall survival is poor, though late onset (>2 years) and strictly localized relapse are favorable prognostic factors.
Stahl et al. (2011) conducted a cohort in Relapsed Ewing sarcoma (n=714). Local relapse vs. Systemic or combined recurrence was evaluated on 5-year overall survival after relapse (OSr) (p=< 0.001). Late relapse (>2 years) and strictly localized relapse of Ewing sarcoma were associated with better 5-year overall survival (29% vs 7% for late vs early relapse; 24% for local relapse, P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: